Illumina
ILMN · NASDAQ · Healthcare
$255.38
+$17.70 (+6.93%) today
Market Cap
$38.56B
24h Volume
$586.7M
P/E Ratio
46.1
52w High
$255.38
52w Low
$91.00
Est. AI Revenue
14%
7-Day Sparkline (Static)
Company facts
Performance
About Illumina
Illumina is a genomic sequencing company. It makes money selling gene sequencing instruments and the consumables those machines use, serving research labs, hospitals, and drug developers reading DNA at scale.
AI accelerates the analysis side. DRAGEN AI Genomics speeds up processing of raw sequencing data, its AI variant caller identifies genetic differences, Connected Insights AI helps interpret results for clinical use, and its genomic AI cloud hosts the workflows.
Founded in 1998 and headquartered in San Diego, California, Illumina trades on the NASDAQ and employs about 8,600 people.
Illumina in the AI buildout
Illumina sits in the AI Healthcare layer of the AI buildout, where its DRAGEN software applies AI to genomic analysis: calling variants, interpreting results, and speeding the path from raw sequence to clinical answer. AI makes its sequencing platform faster and more useful, especially in oncology and rare disease work. But revenue depends on sequencing volumes and instrument cycles, so AI is an enabling feature inside a genomics business rather than a buildout thesis of its own.
ILMN is tracked in AI Healthcare, rated Peripheral on the AI Exposure leaderboard.
By the numbers
52-week range
ILMN trades at $255.38, 100% of the way up its 52-week range of $91.00 to $255.38.
Market cap
Market capitalization is $38.56B, with an AI Exposure Score of 8 out of 100.
Valuation vs peers
Its P/E ratio of 46.1 is above the AI Healthcare category median of 29.6.
Next earnings
Illumina is next expected to report earnings on October 29, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does Illumina do?
Illumina sells gene sequencing instruments and consumables to research labs, hospitals, and drug developers. Its DRAGEN AI software accelerates the analysis of sequencing data for applications like oncology and rare disease.
How is Illumina exposed to AI?
Through analysis software. DRAGEN AI, its variant caller, and Connected Insights apply AI to genomic data, but revenue rides sequencing volumes and instrument cycles. Supercycle rates it an AI Exposure Score of 8 out of 100.
What are Illumina's main AI products?
DRAGEN AI Genomics for fast sequencing analysis, an AI variant caller for identifying genetic differences, Connected Insights AI for clinical interpretation, and a genomic AI cloud hosting those workflows.
Is ILMN a pure play AI stock?
No. Illumina is a genomic sequencing company where AI accelerates analysis but does not drive demand. Its AI Exposure Score of 8 out of 100 reflects that enabling role.
Where is Illumina based and who leads it?
Illumina is headquartered in San Diego, California, and is led by CEO Jacob Thaysen. The company was founded in 1998 and employs about 8,600 people.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.